alexa Effects of ibandronate on bone quality: preclinical studies.
Pharmaceutical Sciences

Pharmaceutical Sciences

Pharmaceutica Analytica Acta

Author(s): Bauss F, Dempster DW

Abstract Share this page

Abstract Osteoporosis is a skeletal disorder characterized by low bone mass and deterioration of bone microarchitecture resulting in bone fragility, which increases the risk of fracture. The clinical efficacy of bisphosphonates is evaluated through improvements in bone mineral density (BMD) and reductions in the risk for fracture. However, as bisphosphonates are administered long term, there is increasing interest in their effects on bone quality, which includes bone mass, strength and architecture. Ibandronate is a potent, nitrogen-containing bisphosphonate with significant antifracture efficacy when administered daily and in regimens with extended between-dose intervals. Clinical studies with ibandronate are supported by an extensive preclinical program that investigated the efficacy and bone safety of ibandronate in various animal models of osteoporosis. In preclinical studies, treatment with ibandronate maintained, or improved the quality, strength and architecture of bone. Intermittent and daily ibandronate regimens provided similar benefits. During ibandronate treatment, the bone retains its capacity for repair and bone mineralization is not adversely affected. Notably, positive relationships among BMD, bone strength and bone architecture have been demonstrated. This review describes the preclinical evidence for the preservation of bone quality with ibandronate, irrespective of the dosing regimen and even when administered at doses higher than those used therapeutically. This article was published in Bone and referenced in Pharmaceutica Analytica Acta

Relevant Expert PPTs

Relevant Speaker PPTs

Recommended Conferences

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords